SIRT1 inhibited AR-dependent prostate cancer cell growth and induced endogenous AR target genes repression while SIRT1 antagonists induced expression of AR-responsive target genes (AR) both in vivo and in vitro (Fu et al., 2006; Kojima et al., 2008). This evidence concerns the gene AR and prostate carcinoma.